Brown Brothers Harriman & Co. Takes Position in Certara, Inc. (NASDAQ:CERT)

Brown Brothers Harriman & Co. purchased a new stake in shares of Certara, Inc. (NASDAQ:CERT) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 2,330,615 shares of the company’s stock, valued at approximately $27,292,000. Brown Brothers Harriman & Co. owned approximately 1.45% of Certara at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CERT. Blue Trust Inc. bought a new position in shares of Certara during the 2nd quarter worth approximately $26,000. Innealta Capital LLC purchased a new stake in shares of Certara during the second quarter valued at approximately $36,000. KBC Group NV lifted its holdings in Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after acquiring an additional 1,584 shares during the period. Intech Investment Management LLC purchased a new position in Certara in the second quarter worth $152,000. Finally, Algert Global LLC bought a new position in Certara in the 2nd quarter valued at $156,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Trading Up 6.0 %

Shares of NASDAQ:CERT opened at $10.36 on Monday. The company has a 50-day moving average price of $10.79 and a two-hundred day moving average price of $13.17. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.87. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. Certara’s revenue was up 10.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.06 EPS. On average, equities analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Insider Buying and Selling

In other news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares of the company’s stock, valued at $1,125,658.16. This trade represents a 33.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CERT. Barclays cut their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Robert W. Baird dropped their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Finally, UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Friday, September 27th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.